Home > Boards > US Listed > Biotechs > Anavex Life Sciences Corp (AVXL)

Dollars to donuts..>8 patients in P2a had sleep issues.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (3) | Next 10 | Previous | Next
XenaLives Member Profile
Member Level 
Followed By 318
Posts 40,893
Boards Moderated 30
Alias Born 09/20/01
160x600 placeholder
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/14/2020 4:38:56 PM
PURA ALERT - MACD Cross Pushing $0.039 50 Day MA With $0.35 Analyst TGT Recommendation InvestorsHub NewsWire - 2/10/2020 12:50:46 PM
PURA BUY Recommendation at $0.03 Issued By AmericanBulls InvestorsHub NewsWire - 2/7/2020 10:33:33 AM
Anavex Life Sciences Reports Fiscal 2020 First Quarter Financial Results and Provides Clinical Study Updates GlobeNewswire Inc. - 2/6/2020 7:00:10 AM
Anavex Life Sciences to Present and Participate in a Panel at the 2020 BIO CEO & Investor Conference GlobeNewswire Inc. - 2/4/2020 7:00:10 AM
Anavex Life Sciences Announces Fast Track Designation Granted by U.S. FDA for ANAVEX®2-73 (blarcamesine) Clinical Developmen... GlobeNewswire Inc. - 2/3/2020 7:00:10 AM
Anavex Life Sciences to Announce Fiscal 2020 First Quarter Financial Results on Thursday, February 6th, 2020 GlobeNewswire Inc. - 1/30/2020 7:00:10 AM
Anavex Life Sciences Announces Achievement of Enrollment Target for the ANAVEX®2-73 (blarcamesine) Phase 2 Parkinson’s Dis... GlobeNewswire Inc. - 1/27/2020 7:00:10 AM
Anavex Life Sciences Issued New U.S. Patent for ANAVEX®2-73 Treatment of Neurodevelopmental Disorders including Rett Syndrom... GlobeNewswire Inc. - 1/8/2020 7:00:10 AM
Anavex Life Sciences Reports Fiscal Year 2019 Financial Results And Provides Clinical Study Updates GlobeNewswire Inc. - 12/16/2019 7:00:10 AM
Anavex Life Sciences to Announce Fiscal 2019 Year End Financial Results on Monday December 16, 2019 GlobeNewswire Inc. - 12/10/2019 7:00:10 AM
Citation Growth Corp. (OTCQX: CGOTF) Weathering the Cannabis Downturn InvestorsHub NewsWire - 12/9/2019 7:23:11 AM
Citation Growth Corp. (OTCQX: CGOTF) Weathering the Cannabis Downturn InvestorsHub NewsWire - 12/9/2019 6:00:00 AM
Anavex Life Sciences Presents ANAVEX®2-73 (blarcamesine) Data at 12th Clinical Trials on Alzheimer's Disease (CTAD) 2019 Con... GlobeNewswire Inc. - 12/4/2019 7:00:10 AM
Anavex Life Sciences Receives Rare Pediatric Disease Designation from FDA for ANAVEX®2-73 (blarcamesine) for the Treatment o... GlobeNewswire Inc. - 11/14/2019 7:00:00 AM
Anavex Life Sciences Announces Publication of Foundational Data for ANAVEX®2-73 (blarcamesine) in Rett Syndrome GlobeNewswire Inc. - 11/6/2019 7:00:00 AM
Anavex Life Sciences Announces ATTENTION-AD ANAVEX®2-73 Extension Clinical Study in Early Alzheimer’s Disease GlobeNewswire Inc. - 10/9/2019 7:00:00 AM
Anavex Life Sciences Issued New U.S. Patent for Composition of Matter Covering ANAVEX®2-73 for the Treatment of Alzheimer’... GlobeNewswire Inc. - 10/2/2019 7:00:00 AM
Anavex Life Sciences Presented at the 6th Annual European Rett Syndrome Conference Preliminary Clinical Efficacy Data from th... GlobeNewswire Inc. - 9/27/2019 3:00:00 AM
Anavex Life Sciences to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference GlobeNewswire Inc. - 9/26/2019 7:00:00 AM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 9/23/2019 6:35:19 AM
Anavex Life Sciences to Present at the Ladenburg Thalmann 2019 Healthcare Conference GlobeNewswire Inc. - 9/18/2019 7:00:00 AM
Post-effective Amendment to Registration Statement (pos Am) Edgar (US Regulatory) - 9/17/2019 5:16:10 PM
CLS Holdings (CLSH) $1.15 Price Target - MASS Approval for Recreational License InvestorsHub NewsWire - 9/17/2019 7:17:00 AM
Withdrawal of Registration Statement (ammendment) (aw) Edgar (US Regulatory) - 9/16/2019 4:17:42 PM
XenaLives Member Level  Monday, 06/24/19 05:57:50 PM
Re: None
Post # of 236812 
Dollars to donuts..>8 patients in P2a had sleep issues.

Poster from CTAD 2018:

Quote:

P146: COMPARISON OF SLEEP MEASUREMENTS FROM
ACTIGRAPHY TO SELF-REPORTED SLEEP DIARIES. Kirsi
Kinnunen1
, Richard Joules1
, Janet Munro1
, Iain Simpson1
, Robin
Wolz1,2, Yves Dauvilliers3 ((1) IXICO Plc, London, UK; (2) Imperial
College London, London - UK; (3) Sleep Unit, Department Neurology,
Centre Hospitalier Universitaire, Montpellier, INSERM 1061 -
France)
Background: Sleep disturbances are common in people living
with dementia. Reduced and fragmented sleep can impact
pathology, worsen other symptoms, and significantly affect
daytime functioning. Additionally, poor sleep quality may
be a risk factor of many neurological conditions, including
Alzheimer’s disease (Ju et al. 2014). While polysomnography
(PSG) remains the gold standard for sleep assessment, it is
costly, often recorded on an isolated night with no daytime
assessment, and may not be feasible in many clinical trials.
The increasing availability of wearable sensor technology
offers a practical, non-intrusive means of collecting continuous
sleep-wake data, over several days. This provides “digital
biomarkers” from real world settings that can be used to
predict risk, detect symptoms and monitor changes in sleep
and activity. Objectives: The aim of this study was to examine
relationships between actigraphy-derived and self-reported
sleep diary measurements within an epidemiology study cohort
of elderly subjects. Methods: We analyzed actigraphy and sleep
diary data, available for 22 subjects (Age: Mean=80.6, SD=9.9;
68% female) from a study of sleep difficulties, lifestyle factors
and general health in the Centre Hospitalier Universitaire,
Montpellier - France. All subjects were asked to wear an Axivity
3-axis accelerometry biosensor device (http://axivity.com/) on
their non-dominant wrist for 14 nights and to complete sleep
diaries for the same 2-week period. IXICO’s fully integrated
wearables work-flow (Figure 1) was employed for data analysis.
This incorporated quality control (QC) for periods of perceived
device “non-wear”. In-bed periods were estimated with the
McVeigh algorithm (McVeigh et al. 2016) and sleep and wake
periods with the Cole-Kripke (CK) algorithm (Cole et al. 1992).
Correlations between the actigraphy- and self-reported sleep
measurements were assessed sample-wise, for all nights with
both types of data available. As part of a quantitative QC,
unrealistic night-time in-bed periods of <2.5 and >13 hours
(N=17) were excluded from subsequent analysis, as well as
self-reported nights with <1 hour of sleep (N=2). This resulted
in 141 nights’ data for the statistical analysis. Correlations
(Pearson’s R/Spearman’s Rho) were calculated between four
variables available from both actigraphy and the diaries: sleep
efficiency/quality, total time in bed, night-time in-bed sleep
and number of awakenings. Results: Actigraphy-derived sleep
efficiency correlated with self-reported sleep quality at r = .16
(p = .06; Figure 2). McVeigh-estimated times in bed at night
and self-reported times from into-bed to out-of-bed correlated
at r = .32 (p = .0001). CK-estimated in-bed sleep times and selfreported times from lights-out to awakening (minus sleep onset
latency) correlated at r = .15 (p = .07). As expected, the number
of estimated night-time awakenings was considerably higher
from actigraphy (median=13, IQR=11) than from the diaries
(median=2, IQR=2), with these measurements correlated at r
= .06 (p = .51). Conclusions: The relatively low correlations
between sleep diaries and actigraphy measures reported here
may implicate poor reliability and inaccuracy of self-reported
sleep measures (see e.g. Goelema et al. 2017). However, as selfreported awakenings may include lying still in bed, the higher
number of actigraphy-derived awakenings may be partially
explained by interpretation of the minute-wise sleep/no-sleep
labeling from the algorithm: a period of wakefulness being
split into several if quiet wakefulness is labelled as asleep. With
sleep efficiency, we have previously shown in the same cohort
that measures derived from 1-night accelerometry recordings
using the CK algorithm (as above) correlated at r = .61 (p =
.003) with simultaneous PSG (Wolz et al. 2017). Using a welldesigned work-flow, actigraphy can provide objective realworld measures of sleep and activity from data collected over 14
days or longer, with minimal patient discomfort and acceptable
QC failure rates. Although PSG can be used to assess sleep
stages, apnea/hypopnea indexes and periodic leg movements,
the advantages of actigraphy over traditional PSG include the
well-tolerated continuous recording in real life settings and
relative cost-effectiveness. The current results suggest that
compared to sleep diaries, actigraphy can offer an attractive
and more reliable alternative for the measurement of signs
and symptoms of disease, or the evaluation of therapeutic
effects. Customized data analytics, including disease-specific
models, have the potential to detect sleep disturbance more
accurately than widely used algorithms such as the CK, which
may incorrectly interpret periods of quiet wakefulness as sleep.
In the Wolz et al. (2017) 1-night study, we found the IXICO
Deep Learning Sleep (DLS) algorithm to outperform the CK
in estimating PSG-derived sleep efficiency (DLS: r = .84, p <
.0001 vs. CK: r = .61, p = .003). Our approach of combining
actigraphy with advanced data analytics shows promise for
providing improved biomarkers of sleep, circadian rhythm
and activity outcomes in clinical trials. In future work, we
will employ the DLS algorithm to estimate sleep efficiency in
elderly populations and neurodegenerative disease cohorts
and will extend the presented statistical analysis to include
daytime naps and an assessment of variability between night
and day activity/sleep over the 14 day period. References:Cole
et al. (1992). Automatic sleep/wake identification from wrist
activity. Sleep, 12(5), 461–9. Goelema et al. (2017). Determinants
of perceived sleep quality in normal sleepers. Behavioural
Sleep Medicine, (20):1-10. Ju, et al. (2014). Sleep and Alzheimer
disease pathology--a bidirectional relationship. Nature Reviews
Neurology, 10(2), 115–9. McVeigh et al. (2016). Validity of an
automated algorithm to identify waking and in-bed wear time
in hip-worn accelerometer data collected with a 24 h wear
protocol in young adults. Physiological Measurement, 37(10),
1636–52. Wolz et al. (2017). Extracting digital biomarkers of
sleep from 3-axis accelerometry using deep learning. The
Journal of Prevention of Alzheimer’s Disease, 4(4), P81.




https://www.ctad-alzheimer.com/files/files/CTAD%20ABSTRACT.pdf



In Peace, In War
Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (3) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist